NASDAQ, TSX: NVCN First implant of a Neovasc Reducer™ in a U.S. patient Reducer Q2, 2018 revenue up 64% over Q2, 2017 and at 108% of Q2, 2018 plan Tiara™ featured in live case at 11th Annual TVT conference Receipt of proceeds of US$13.1 million from exercise of Series...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Aug. 8, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is now scheduled to...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry -...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Aug. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Aug. 2, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the quarter and six months ended June...
Read MoreVANCOUVER, July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has scheduled an oral hearing for August 30,...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base shelf prospectus (the "Base Shelf Prospectus") filed with securities regulatory authorities in the provinces of British...
Read More